CIAM
BCAX

Caitong International Asset Management’s Bicara Therapeutics BCAX Stock Holding History

Caitong International Asset Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.02K Sell
169
-2,375
-93% -$53K ﹤0.01% 1290
2026
Q1 		$50.6K Sell
2,544
-3,231
-56% -$55.6K 0.01% 786
2025
Q4 		$97.2K Buy
5,775
+4,585
+385% +$78.3K 0.02% 437
2025
Q3 		$18.8K Buy
+1,190
New +$13.3K 0.01% 735
2025
Q1 		– Sell
-76
Closed -$1.32K – 2584
2024
Q4 		$1.32K Buy
+76
New +$1.58K ﹤0.01% 1269

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Caitong International Asset Management's BCAX Position: Q2 2026 in Review

Caitong International Asset Management reduced its Bicara Therapeutics (BCAX) stake by 93% in Q2 2026, selling an estimated $53K and leaving 169 shares worth $5.02K. The position accounts for ﹤0.01% of the portfolio, ranked #1290.

Caitong International Asset Management first reported a position in BCAX in Q4 2024 and has held it in 5 quarters since. The position peaked at $97.2K in Q4 2025. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Caitong International Asset Management held 169 shares of Bicara Therapeutics worth $5.02K as of Q2 2026.
  • Caitong International Asset Management sold 2,375 Bicara Therapeutics shares in Q2 2026, an estimated $53K.
  • Bicara Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #1290 holding.
  • Caitong International Asset Management first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • Caitong International Asset Management's Bicara Therapeutics position peaked at $97.2K in Q4 2025.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.